Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Medicare, Ozempic and Wegovy
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Half of Americans Support Weight-Loss Drugs Like Ozempic for Obesity, Poll
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching hundreds of dollars per prescription. The poll found that about half of Americans support Medicare and Medicaid covering weight-loss drugs for those with obesity, while around 20 percent oppose it and 25 percent are neutral.
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Medicare to Negotiate Lower Prices for Weight-Loss Drugs
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
About half of Americans approve of using weight-loss drugs to treat obesity, new poll finds
New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are struggling with obesity
Popular weight loss drugs could be cheaper for some Americans: What you need to know
If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as cancer, asthma, type 2 diabetes and weight loss - Ozempic, Rybelsus and Wegovy. Austedo and Austedo XR, used to treat Huntington’s disease.
Hollywood's use of Ozempic as 'weight loss drug' sees surge in public use
EXCLUSIVE: Hollywood's Ozempic use has been steadily rising with many celebrities crediting the drug for their weight loss, which has seen the public keen to do the same.
14d
Medicare announces weight-loss drugs, including Ozempic, will be up for price negotiations
The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.
3d
on MSN
RFK Jr, Dr Oz and weight-loss drugs: A high-price health clash may be looming
Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's ...
CBS News on MSN
14d
Medicare drug price negotiations to target Ozempic, Wegovy and other drugs
The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.
STAT
14d
Medicare announces plan to negotiate prices of diabetes, weight loss drugs
WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic ...
14d
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly ...
14d
Medicare to negotiate prices for weight loss drugs: What to know
The Biden administration says it will be including weight loss drugs like Ozempic and Wegovy in the next round of drug ...
1d
The high cost of weight loss: How patients are fighting for access to breakthrough medications
CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...
20h
on MSN
Billionaire Philippe Laffont Just Sold Top Artificial Intelligence Stocks Nvidia and AMD and Piled Into 2 Players Dominating Another High-Growth Billion-Dollar Industry
As founder of Coatue Management, Philippe Laffont oversees $26.9 billion invested in more than 80 stocks, and though he buys ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback